NovAccess Global Announces Series of Fireside Chats for the Investor Community

CLEVELAND, OH /ACCESSWIRE/September 29, 2022/ NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that it will conduct a series of monthly executive interviews over the next four months, with additional sessions to be made available as the business develops. The interviews are intended to cover important and timely topics related to the company, its platform technologies, and the global healthcare and business environments.

NovAccess Global Fireside Chat Series Schedule:

The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as listed below:

October 6, 2022 – Insights from NovAccess Global Board Members – Biomedical and Shareholder Opportunities

Speakers: certain executive and non-executive members of the company’s board of directors

November 3, 2022 – Advocacy for patients’ rights

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

December 1, 2022 – Advantages of Immunotherapy over Surgical Treatment

Speaker: Dr. Christopher Wheeler, Ph.D., President of StemVax Therapeutics Inc., a division of NovAccess Global

January 5, 2023 – Brian’s Glioblastoma and Tumor Market

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

The interviews will be streamed for public viewing on the Internet and will be available for viewing on the dates noted in this press release via links made available in the Webcasts and Presentations section of the NovAccess Global website at www.novaccessglobal.com and on all Company social media feeds.

About NovAccess Global

NovAccess Global is a biomedical company accelerating new cancer diagnostics and treatments. Our goal is to discover, develop and bring to market new and innovative drugs and medical devices to improve the quality of care for patients with cancer and neurological diseases.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors. Our company has a new immunotherapeutic approach to treat brain tumor patients with glioblastoma, the most common adult brain tumor with a median survival of 15 months after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor. Our technology platform focuses on enhancing the patient’s immune cells to fight their unique cancer using the patient’s tumor-specific antigens. This is a significant technology that could dramatically improve the quality of life and prognosis for many people with brain tumours. For more information, please visit novaccessglobal.com.

Forward-looking statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “shall” or “should”, “expects”, “anticipates”, “draft”, “possibly” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ. significantly from those projected. in forward-looking statements due to various factors and other risks identified in the Company’s disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of small companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy these stocks unless they can afford the loss of all of his investment. The Company disclaims any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

This press release and the interviews that will be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell or a solicitation of an offer to buy securities. Interview participants have agreed to participate in this series of events and no compensation will be paid or provided to them or their respective organizations. Entry does not represent an offer to buy or sell securities to or from any person or other entity through their platforms. Before making any investment in or subscribing to any of the platforms that may be associated with the Fireside Chat Series and the redistribution of related content, listeners/viewers are encouraged to seek financial, legal, and tax professional to assist with due diligence. as appropriate to determine the risk associated with any investment.

Contact with Investor Relations:

Jordan Darrow
Darrow Associates
631-766-4528
[email protected]

THE SOURCE: Darrow Associates, Inc.